Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024 Press Release Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024
Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc. Press Release Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.
Naveris Receives Medicare Coverage for NavDx® Test Press Release Naveris Receives Medicare Coverage for NavDx® Test
Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice Press Release Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice
Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings Press Release Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings
Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial Press Release Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial
Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers Press Release Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers
Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx Press Release Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx
Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting Press Release Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting
Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session Press Release Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session
